Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03598010
Other study ID # ABO-LEN-02/19
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 2019
Est. completion date March 2021

Study information

Verified date May 2019
Source Aboca Spa Societa' Agricola
Contact Niccolò Ravenni, PhD
Phone +39 0575 746
Email clinicaltrials@aboca.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluation of the efficacy of a treatment with Actitan-F, a natural molecular complex of tannins (from Agrimony and Tormentil) and flavonoids (Chamomile) in a pediatric population of children affected by acture/prolonged/chronic diarrhea


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 240
Est. completion date March 2021
Est. primary completion date December 2020
Accepts healthy volunteers No
Gender All
Age group 1 Year to 12 Years
Eligibility Inclusion Criteria

1. Children of either sex aged between 1-12 years (inclusive);

2. Evidence of acute (onset <7 days prior to screening visit), prolonged (onset between 7 and 14 days prior to screening visit) or chronic (onset >14 days prior to screening visit) diarrhea.

- Acute/Prolonged Diarrhea is defined as at least 3 evacuations of loose or watery stools (stools type 6-7 of Bristol scale) occurring in the 24 hours preceding the screening visit.

- Chronic Diarrhea (>14 days duration), defined by passage of loose or watery stools (Bristol score 6 or 7) with or without an increase in frequency of bowel movements;

3. Evidence of mild to moderate dehydration, defined as a score 1-4 in the Clinical Dehydration Scale;

4. Parents/legal guardians availability to fill on a daily basis the electronic daily diary by a smartphone/tablet/laptop.

5. Parents/legal guardians* have given a written informed consent for participation in the study at the time of enrolment or before. The parent/legal guardian should also have agreed to bring the child for the visits scheduled in the protocol and to provide the requested information during the telephonic follow-up visit;

6. Parents/legal guardian able to understand the full nature and the purpose of the investigation, including possible risks and side effects, able to cooperate with the Investigator and to comply with the requirements of the entire investigation (ability to attend all the planned investigation visits according to the time limits included) based on Investigator's judgement.

Exclusion Criteria:

Exclusion Criteria

1. Children of female sex having started menarche;

2. Evidence of severe dehydration, defined as a score > 4 in the Clinical Dehydration Scale;

3. Known hypersensitivity to any of the components (active ingredients or excipients) of the investigational product;

4. Severely malnourished patients, defined as those patients with body weight < 50% for age;

5. History of immune diseases or conditions known to producing immunodeficiency (AIDS, other congenital immunodeficiency syndromes, anticancer drugs, etc.);

6. For acute/prolonged diarrhea only, patients who have received any of the following treatments within the 2 weeks before the screening/baseline visit:

- Drugs with adsorbing properties, e.g. kaolin, pectin, bismuth subsalicylate;

- Drugs that modify intestinal secretions, e.g. racecadotril;

- Drugs that modify intestinal motility, e.g. opiates such as loperamide, atropine and other anti-cholinergic agents);

- Laxatives

- Antibiotics

7. History of seizures due to known or unknown causes;

8. Parents/legal guardians' refusal or inability to give written informed consent to participate in the study;

9. Parents/legal guardians who, in the opinion of the Investigator, are unable to fill up the electronic patient diary;

10. Patients who may not be possible to come for the scheduled visits;

11. Patients who have participated in any other clinical trial in the last 3 months prior to the start of the study.

Study Design


Intervention

Device:
Actitan-F (7dd)
1 sack every 4 hours, maximum 4 sacks/day for 7 days.
Actitan-F (28dd)
1 sack every 4 hours, maximum 4 sacks/day for 28 days.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Aboca Spa Societa' Agricola

Outcome

Type Measure Description Time frame Safety issue
Primary Acute (onset <7 days) or Prolonged Diarrhea (onset =7 and =14 days): Response Rate (RR) measured after 4 treatment days. Acute (onset <7 days) or Prolonged Diarrhea (onset =7 and <14 days): Response Rate (RR) measured after 4 treatment days. Patients will be considered as responders if they have experienced the passage of 2 formed stools or no stool for at least 12 consecutive hours during the 4 days treatment. Day0 to Day4
Primary Chronic Diarrhea (onset >14 days): Response Rate (RR) measured across the whole treatment period Chronic Diarrhea (onset >14 days): Response Rate (RR) measured across the whole treatment period (4 weeks). Patients will be considered as responders if they have experienced a 50% (or more) reduction in the number of days with at least 1 diarrheic stools (Bristol score 6 or 7) in the whole treatment period (4 weeks) compared to the 7 days prior the treatment (baseline). Day0 to Day28
Secondary Number of episodes of daily watery evacuations Number of episodes of daily watery evacuations evaluated by means of the electronic patient diaries; Day0-Day28
Secondary Number of unformed stools passed per 24-h interval, after the first dose Number of unformed stools passed per 24-h interval, after dosing evaluated by means of the electronic patient diaries Day0-Day28
Secondary Number of treatment failures Number of treatment failures. A treatment failure is defined as clinical deterioration or worsening of symptoms or illness continuing after 120 h following the first dose evaluated by means of the electronic patient diaries Day0-Day28
Secondary Difference in body weight Difference in body weight between baseline and End of Treatment Day0-Day28
Secondary Frequency and severity of diarrhea associated symptoms Frequency and severity of diarrhea associated symptoms (nausea, vomiting, abdominal pain). Severity will be evaluated by means of a 0-4 Likert scale (0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = very severe); Day0-Day28
Secondary Treatment Compliance Evaluation of the nr of sachets prescribed by the investigators and the % of compliance recorded Day0-Day28
Secondary Proportion of patients requiring other (allowed) treatments Proportion of patients requiring other treatments in addition to Lenodiar Pediatric or to other concomitant treatments prescribed at baseline visit for diarrhea symptoms relief (e.g. parenteral rehydration and/or other medications) evaluated by means of the electronic patient diaries Day0-Day28
Secondary Change in results of the Pediatric Quality of Life Questionnaire (PedsQL) Change in results of the Pediatric Quality of Life Questionnaire (PedsQL) between baseline and End of Treatment visits Day0-Day28
Secondary Change in results in parent assessment of children Quality of Life (100 mm VAS) Change in results in parent assessment of children Quality of Life (100 mm VAS) between baseline and End of Treatment visits Day0-Day28
Secondary Safety and tolerability of the treatment: Incidence of adverse events (AEs) and serious adverse events (SAEs), and rate of study discontinuations due to AEs/SAE; Incidence of adverse events (AEs) and serious adverse events (SAEs), and rate of study discontinuations due to AEs/SAE; Day0-Day28
See also
  Status Clinical Trial Phase
Completed NCT06283784 - Study To Evaluate The Efficacy of a Proprietary Mix of Live Probiotics In The Prophylaxis Of Diarrhea In Adult Patients N/A
Recruiting NCT03851835 - Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis Phase 3
Completed NCT04003181 - The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon N/A
Completed NCT03596827 - The Protective Immune Response to Attenuated Enterotoxigenic Escherichia Coli Infection N/A
Recruiting NCT05372068 - Cement flooRs AnD chiLd hEalth (CRADLE) N/A
Completed NCT03972618 - Evaluation of the Efficacy of Sawyer Point One Filters in Schools and Homes in the Dominican Republic N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT05052489 - Registry and Clinical Observation of Children With Diarrhoeal Disease
Completed NCT02541695 - Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli N/A
Completed NCT02428647 - Lao Zinc Study: Effects of Two Forms of Daily Preventive Zinc Versus Therapeutic Zinc Supplementation N/A
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Completed NCT01739231 - Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults Phase 1/Phase 2
Completed NCT01968408 - Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children Phase 3
Terminated NCT01472211 - Water-based Zinc Intervention Trial in Zinc Deficient Children Phase 0
Completed NCT01438645 - ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy N/A
Terminated NCT01048567 - Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly Phase 2
Completed NCT01371656 - Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Phase 3
Not yet recruiting NCT01382199 - Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients Phase 3
Completed NCT00914225 - Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya N/A
Completed NCT00760851 - Yogurt Study in Children 2-4 Years Old Attending Daycare Phase 3